Next Article in Journal
Transcriptomic Stress Response in Streptococcus mutans following Treatment with a Sublethal Concentration of Chlorhexidine Digluconate
Next Article in Special Issue
WGS-Based Phenotyping and Molecular Characterization of the Resistome, Virulome and Plasmid Replicons in Klebsiella pneumoniae Isolates from Powdered Milk Produced in Germany
Previous Article in Journal
Verification and Use of the US-FDA BAM 19b Method for Detection of Cyclospora cayetanensis in a Survey of Fresh Produce by CFIA Laboratory
Previous Article in Special Issue
Molecular Epidemiology of Multidrug-Resistant Pneumococci among Ghanaian Children under Five Years Post PCV13 Using MLST
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 10
Issue 3
10.3390/microorganisms10030560
Review Report
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae

Microorganisms 2022, 10(3), 560; https://doi.org/10.3390/microorganisms10030560
by Thomas Chandler 1,*, Stephen Furmanek 1, Ruth Carrico 1,2, Dawn Balcom 2, Forest Arnold 2 and Julio Ramirez 1,2,†
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Microorganisms 2022, 10(3), 560; https://doi.org/10.3390/microorganisms10030560
Submission received: 28 January 2022 / Revised: 24 February 2022 / Accepted: 25 February 2022 / Published: 4 March 2022
(This article belongs to the Special Issue Pneumococcal Pneumonia: Epidemiology, Pathophysiology, Treatment and Vaccines)

Round 1

Reviewer 1 Report

Review report for the manuscript “ 23-valent pneumococcal polysaccharide vaccination does not  prevent community-acquired pneumonia hospitalizations due  to vaccine-type Streptococcus pneumoniae”.

 

General comment:  The manuscript presented for review is well-written. The study by   Chandler et al. highlights the need for  more effective vaccines in the prevention of hospitalization due to S. pneumoniae CAP. Their findings suggest that vaccination with the PPSV23 fails to offer protection 234 against hospitalization due to PPSV23-serotype CAP.

 

Overall, this is a clear and well-organized manuscript.

 

I have a minor comment:

Line 102 , 120, 121..  Please standardize the 'p' throughout the manuscript.

Author Response

Point 1: Line 102, 120, 121. Please standardize the 'p' throughout the manuscript.

 

Response 1: Thank you for taking the time to review and provide comments on our manuscript. We hope that the results of our study will assist providers in administering the most effective pneumococcal vaccine in eligible patients. We agree with the reviewers comments and have standardized the “p” throughout the manuscript.

Reviewer 2 Report

Authors successfully investigated whether  23-valent pneumococcal polysaccharide vaccination prevents PPSV23-serotype CAP hospitalization in adults. The approach is novel and for the first-time effectiveness of the PPSV23 was investigated using urinary antigen detection as the assay for serotyping. Data inclusions and exclusions were acceptable and justification is appropriate. The data presentation and interpretation was appropriate. The manuscript can be accepted as it is.

Author Response

Thank you for taking the time to review and provide comments on our manuscript. We hope that the results of our study will assist providers in administering the most effective pneumococcal vaccine in eligible patients.

Back to TopTop